Sigilon Announces Reverse Stock Split of Common Stock
SGTXDelisted Stock | USD 21.11 0.33 1.54% |
Slightly above 62% of Sigilon Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Sigilon Therapeutics suggests that many traders are alarmed regarding Sigilon Therapeutics' prospects. Sigilon Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Sigilon Therapeutics' earnings reports, geopolitical events, and overall market trends.
Sigilon |
CAMBRIDGE, Mass., May 22, 2023 Sigilon Therapeutics, Inc. today announced it will effect a one-for-13 reverse stock split of its issued and outstanding common stock. Sigilon stockholders approved an amendment to Sigilons Fifth Amended and Restated Certificate of Incorporation to effect the reverse stock split at Sigilons Annual Meeting of Stockholders held on May 19, 2023. The reverse stock split is intended to increase the per share trading price of Sigilon
Read at finance.yahoo.com
Sigilon Therapeutics Fundamental Analysis
We analyze Sigilon Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sigilon Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sigilon Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
Sigilon Therapeutics is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Sigilon Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Sigilon Therapeutics stock to make a market-neutral strategy. Peer analysis of Sigilon Therapeutics could also be used in its relative valuation, which is a method of valuing Sigilon Therapeutics by comparing valuation metrics with similar companies.
Peers
Sigilon Therapeutics Related Equities
XFOR | X4 Pharmaceuticals | 11.43 | ||||
RVPH | Reviva Pharmaceuticals | 8.77 | ||||
PHIO | Phio Pharmaceuticals | 3.03 | ||||
NBY | NovaBay Pharmaceuticals | 1.69 | ||||
UNCY | Unicycive Therapeutics | 1.47 | ||||
INM | InMed Pharmaceuticals | 0.23 | ||||
SONN | Sonnet Biotherapeutics | 2.28 | ||||
GOVX | GeoVax Labs | 2.58 | ||||
CDIO | Cardio Diagnostics | 3.23 | ||||
ZVSA | ZyVersa Therapeutics | 3.60 | ||||
APLM | Apollomics | 15.62 |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Other Consideration for investing in Sigilon Stock
If you are still planning to invest in Sigilon Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sigilon Therapeutics' history and understand the potential risks before investing.
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories |